The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
REGULATORY
1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
The first biosimilar versions of the G-CSF agent G-Lasta (pegfilgrastim) in Japan will join the NHI price list on November 22, along with a fourth follow-on of the anti-TNFα antibody Humira (adalimumab), according to the government’s official gazette issued on…
To read the full story
Related Article
- High Demand Triggers Shipment Curb for G-Lasta Biosimilars
March 14, 2024
- Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
December 13, 2023
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
- Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
REGULATORY
- Discussions on Generic Company Indices Make Headway towards Full Rollout in Next Revision
December 13, 2024
- CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
- Chuikyo Doctor Rep Positive on Industry’s Behavioral Changes after 2024 Reform
December 12, 2024
- JGA to Compile Interim Report on Generic Industry Revamp in May
December 12, 2024
- Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…